We examine a number of factors including clinicopathological features of the primary tumour, lymph node metastasis, and the CCND1 and EGFR gene status of primary tumours, and evaluate the value of predicting the risk of ECS of metastatic lymph nodes. This evidence concerns the gene CCND1 and metastatic malignant neoplasm in the lymph nodes.